Publicaciones en colaboración con investigadores/as de Karolinska Institute (12)

2023

  1. Bortezomib-Dexamethasone, Rituximab, and Cyclophosphamide as First-Line Treatment for Waldenström's Macroglobulinemia: A Prospectively Randomized Trial of the European Consortium for Waldenström's Macroglobulinemia

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 41, Núm. 14, pp. 2607-2616

  2. Differences in the immunoglobulin gene repertoires of IgG versus IgA multiple myeloma allude to distinct immunopathogenetic trajectories

    Frontiers in Oncology, Vol. 13

  3. Report of consensus Panel 4 from the 11th International Workshop on Waldenstrom's macroglobulinemia on diagnostic and response criteria

    Seminars in Hematology

  4. Report of consensus panel 5 from the 11th international workshop on Waldenstrom's macroglobulinemia on COVID-19 prophylaxis and management

    Seminars in Hematology

  5. Report of consensus panel 7 from the 11th international workshop on Waldenström macroglobulinemia on priorities for novel clinical trials

    Seminars in Hematology

2021

  1. Validation of the EuroClonality-NGS DNA capture panel as an integrated genomic tool for lymphoproliferative disorders

    Blood Advances, Vol. 5, Núm. 16, pp. 3188-3198

2020

  1. A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenström macroglobulinemia: The ASPEN study

    Blood, Vol. 136, Núm. 18, pp. 2038-2050

2018

  1. ERIC recommendations for TP53 mutation analysis in chronic lymphocytic leukemia - Update on methodological approaches and results interpretation

    Leukemia, Vol. 32, Núm. 5, pp. 1070-1080

2016

  1. International Myeloma Working Group Recommendations for the Diagnosis and Management of Myeloma-Related Renal Impairment

    Journal of Clinical Oncology, Vol. 34, Núm. 13, pp. 1544-1557

  2. Treatment recommendations from the Eighth International Workshop on Waldenström's Macroglobulinemia

    Blood, Vol. 128, Núm. 10, pp. 1321-1328

2015

  1. American Society of Blood and Marrow Transplantation, European Society of Blood and Marrow Transplantation, Blood and Marrow Transplant Clinical Trials Network, and International Myeloma Working Group Consensus Conference on Salvage Hematopoietic Cell Transplantation in Patients with Relapsed Multiple Myeloma

    Biology of Blood and Marrow Transplantation, Vol. 21, Núm. 12, pp. 2039-2051

2004

  1. Differential stability of control gene and fusion gene transcripts over time may hamper accurate quantification of minimal residual disease - A study within the Europe against cancer program [9]

    Leukemia